Tags

Type your tag names separated by a space and hit enter

Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.
Diagn Microbiol Infect Dis. 2008 Jun; 61(2):203-13.DM

Abstract

Since 1997, the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program has monitored the antimicrobial activity of broad-spectrum agents against pathogens from hospitalized patients. In the United States, 2894 isolates were submitted in 2007 from 15 sites, including 1392 Enterobacteriaceae, 643 nonfermentative Gram-negative bacilli, and 829 Gram-positive cocci. All isolates were tested by broth microdilution methods. Meropenem (MIC(90) range, 0.12-2 microg/mL) exhibited the lowest resistance rates (1.9-2.4%) against Enterobacteriaceae, and fluoroquinolones had the highest rates of resistance (17.3-18.3%). KPC carbapenemases, usually found in Klebsiella pneumoniae, were also detected in Citrobacter freundii, Enterobacter spp., and Escherichia coli. Confirmed extended-spectrum beta-lactamase-producing isolate rates for E. coli, Klebsiella spp., and Proteus mirabilis isolates were 6.0%, 12.0%, and 0.0%, respectively. Meropenem remained active against Gram-positive pathogens such as staphylococci (methicillin-susceptible; MIC(90), 0.12-0.25 microg/mL), Streptococcus pneumoniae (MIC(90), 0.5 microg/mL), and beta-hemolytic and viridans group streptococci (MIC(90) range, 0.06-0.25 microg/mL). These US MYSTIC Program results demonstrate the continued emergence of novel beta-lactamases and multidrug-resistant bacterial phenotypes necessitating monitoring of carbapenem activities against Enterobacteriaceae species as well as nonfermentative bacilli.

Authors+Show Affiliations

JMI Laboratories, North Liberty, IA 52317, USA. ronald-jones@jmilabs.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18329835

Citation

Jones, Ronald N., et al. "Comparative Activity of Meropenem in US Medical Centers (2007): Initiating the 2nd Decade of MYSTIC Program Surveillance." Diagnostic Microbiology and Infectious Disease, vol. 61, no. 2, 2008, pp. 203-13.
Jones RN, Kirby JT, Rhomberg PR. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagn Microbiol Infect Dis. 2008;61(2):203-13.
Jones, R. N., Kirby, J. T., & Rhomberg, P. R. (2008). Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagnostic Microbiology and Infectious Disease, 61(2), 203-13. https://doi.org/10.1016/j.diagmicrobio.2008.01.017
Jones RN, Kirby JT, Rhomberg PR. Comparative Activity of Meropenem in US Medical Centers (2007): Initiating the 2nd Decade of MYSTIC Program Surveillance. Diagn Microbiol Infect Dis. 2008;61(2):203-13. PubMed PMID: 18329835.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. AU - Jones,Ronald N, AU - Kirby,Jeffrey T, AU - Rhomberg,Paul R, Y1 - 2008/03/10/ PY - 2008/01/03/received PY - 2008/01/16/revised PY - 2008/01/17/accepted PY - 2008/3/11/pubmed PY - 2008/7/25/medline PY - 2008/3/11/entrez SP - 203 EP - 13 JF - Diagnostic microbiology and infectious disease JO - Diagn. Microbiol. Infect. Dis. VL - 61 IS - 2 N2 - Since 1997, the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program has monitored the antimicrobial activity of broad-spectrum agents against pathogens from hospitalized patients. In the United States, 2894 isolates were submitted in 2007 from 15 sites, including 1392 Enterobacteriaceae, 643 nonfermentative Gram-negative bacilli, and 829 Gram-positive cocci. All isolates were tested by broth microdilution methods. Meropenem (MIC(90) range, 0.12-2 microg/mL) exhibited the lowest resistance rates (1.9-2.4%) against Enterobacteriaceae, and fluoroquinolones had the highest rates of resistance (17.3-18.3%). KPC carbapenemases, usually found in Klebsiella pneumoniae, were also detected in Citrobacter freundii, Enterobacter spp., and Escherichia coli. Confirmed extended-spectrum beta-lactamase-producing isolate rates for E. coli, Klebsiella spp., and Proteus mirabilis isolates were 6.0%, 12.0%, and 0.0%, respectively. Meropenem remained active against Gram-positive pathogens such as staphylococci (methicillin-susceptible; MIC(90), 0.12-0.25 microg/mL), Streptococcus pneumoniae (MIC(90), 0.5 microg/mL), and beta-hemolytic and viridans group streptococci (MIC(90) range, 0.06-0.25 microg/mL). These US MYSTIC Program results demonstrate the continued emergence of novel beta-lactamases and multidrug-resistant bacterial phenotypes necessitating monitoring of carbapenem activities against Enterobacteriaceae species as well as nonfermentative bacilli. SN - 0732-8893 UR - https://www.unboundmedicine.com/medline/citation/18329835/Comparative_activity_of_meropenem_in_US_medical_centers__2007_:_initiating_the_2nd_decade_of_MYSTIC_program_surveillance_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732-8893(08)00069-2 DB - PRIME DP - Unbound Medicine ER -